BofA Securities stays Underperform on ProKidney Corp. (PROK) after earnings on trial risk
Tweet Send to a Friend
BofA Securities analyst Jason Gerberry reiterated an Underperform rating and $1.00 price target on ProKidney Corp. (NASDAQ: PROK)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
